A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
NCT07656415 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 159
Last updated 2026-08-04
Summary
The primary objective of this study is to determine the effect of mitapivat versus placebo on the need for transfusions in subjects with SCD.
Conditions
Interventions
- DRUG
-
Mitapivat Matched Placebo
Tablets
- DRUG
-
Mitapivat
Tablets
Sponsors & Collaborators
-
Agios Pharmaceuticals, Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-07-21
- Primary Completion
- 2029-08-31
- Completion
- 2030-08-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
NCT04770779 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
NCT05861453 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Sickle CEll Disease ComplicatioN Trial
NCT02604368 ·Status: UNKNOWN ·Phase: PHASE3
-
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease
NCT01522547 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
NCT04055818 ·Status: RECRUITING ·Phase: PHASE1
-
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
NCT04770753 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
NCT06363760 ·Status: ENROLLING_BY_INVITATION
-
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
NCT05036512 ·Status: COMPLETED ·Phase: PHASE1
-
A GBT021601 ADME Microtracer Study in Healthy Volunteers
NCT05718687 ·Status: COMPLETED ·Phase: PHASE1
-
Imatinib for Pain in Sickle Cell Anemia
NCT03997903 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients
NCT03815695 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
NCT06198712 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268 ·Status: RECRUITING ·Phase: PHASE3
-
A Research Study of the Effect of Food on Etavopivat in Healthy Participants
NCT06433661 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)
NCT03285178 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
NCT05777993 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
NCT05660265 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
NCT03132324 ·Status: TERMINATED ·Phase: PHASE1
-
Dose-Escalation Study of SCD-101 in Sickle Cell Disease
NCT02380079 ·Status: UNKNOWN ·Phase: PHASE1
-
Decitabine for High-Risk Sickle Cell Disease
NCT01375608 ·Status: COMPLETED ·Phase: PHASE2
-
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
NCT02567695 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease
NCT04536792 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease
NCT04255875 ·Status: COMPLETED ·Phase: PHASE1